Holen Sie sich die Stockscreener-App
6.99
0.99%
-0.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt GRFS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$7.06
Offen:
$6.92
24-Stunden-Volumen:
2.13M
Relative Volume:
2.20
Marktkapitalisierung:
$4.75B
Einnahmen:
$7.57B
Nettoeinkommen (Verlust:
$216.85M
KGV:
22.02
EPS:
0.3174
Netto-Cashflow:
$709.16M
1W Leistung:
+1.16%
1M Leistung:
-11.07%
6M Leistung:
-3.45%
1J Leistung:
-16.69%
1-Tages-Spanne:
$6.87
$7.105
1-Wochen-Bereich:
$6.61
$7.105
52-Wochen-Spanne:
$5.3001
$9.96
Grifols Sa Adr Stock (GRFS) Company Profile
Vergleichen Sie GRFS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
6.99 | 4.75B | 7.57B | 216.85M | 709.16M | 0.3174 |
|
LLY
Lilly Eli Co
|
870.37 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.17 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.51 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.97 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
88.05 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-12 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-04-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2022-04-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Herabstufung | Barclays | Overweight → Underweight |
| 2021-10-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-06-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Hold |
| 2021-03-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Hochstufung | HSBC Securities | Hold → Buy |
| 2020-10-01 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-06-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-06-09 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-06-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Herabstufung | Berenberg | Buy → Hold |
| 2018-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2018-06-01 | Eingeleitet | Barclays | Overweight |
| 2017-10-31 | Eingeleitet | Citigroup | Buy |
| 2017-06-30 | Herabstufung | Goldman | Buy → Neutral |
| 2017-04-06 | Eingeleitet | BofA/Merrill | Buy |
| 2017-01-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Hochstufung | Berenberg | Hold → Buy |
| 2016-01-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Herabstufung | HSBC Securities | Buy → Hold |
| 2015-11-20 | Herabstufung | Berenberg | Buy → Hold |
| 2015-04-28 | Herabstufung | Berenberg | Buy → Hold |
Alle ansehen
Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Barchart
BRF S.A. goes ex dividend tomorrow - MSN
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - MSN
Grifols falls amid potential Moody's downgrade, new short report - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Is it possible to buy Grifols SA ADR(GRFS) shares at a good price now? - US Post News
Grifols SA ADR (GRFS)’s Day in Review: Closing at 8.58, Down by -0.12 - The Dwinnex
RFID Kanban Systems Market Forecast to Reach $9.53 Billion by 2030 - GlobeNewswire Inc.
A Look at Grifols SA ADR (GRFS) Shares in the Recent Past Indicates Growth - SETE News
Cboe Global Markets Inc. (AMEX: CBOE): Getting A Free Pass? - Stocks Register
It is Poised to be a Bull Market for Grifols SA ADR (GRFS) - SETE News
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Examining Grifols SA ADR (GRFS) stock is warranted - US Post News
Are Grifols SA ADR’shares a good deal? - US Post News
Orange To Delist From NYSE To Reduce Financial Burdens - Yahoo Finance
Financial Health Report: Grifols SA ADR (GRFS)’s Ratios Tell a Tale - The Dwinnex
Was anything negative for Grifols SA ADR (GRFS) stock last session? - US Post News
Ratio Review: Analyzing Grifols SA ADR (GRFS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GRFS’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
How does Grifols SA ADR (GRFS) change from a tortoise to a hare? - SETE News
Mexico Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
The Significance of Moving Averages in Grifols SA ADR Inc. (GRFS) Price Performance - The InvestChronicle
Have you been able to find a good deal on Grifols SA ADR’s shares? - US Post News
Closing Figures: Grifols SA ADR (GRFS)’s Negative Finish at 8.41, Down -1.87 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: Grifols SA ADR (GRFS) - SETE News
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Analytical Overview: Grifols SA ADR (GRFS)’s Ratios Tell a Financial Story - The Dwinnex
Investing in Grifols SA ADR (GRFS) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Grifols Class B stock falls as Brookfield reportedly seeks lower price - MSN
Grifols Class B stock discounted by Brookfield (NASDAQ:GRFS) - Seeking Alpha
An analyst sees good growth prospects for Grifols SA ADR (GRFS) - SETE News
Grifols SA ADR [GRFS] Is Currently 1.11 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Grifols SA ADR (GRFS)’s Market Momentum: Closing Strong at 9.00, Up 2.74 - The Dwinnex
Grifols SA ADR (GRFS) looking to reclaim success with recent performance - SETE News
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Is the Grifols SA ADR (NASDAQ:GRFS) stock an investment opportunity? - US Post News
Grifols shares up on potential takeover by Brookfield - Investing.com
Market Update: Grifols SA ADR (GRFS) Sees Positive Movement, Closing at 7.18 - The Dwinnex
XPeng Inc. Sponsored ADR (XPEV) Laps the Stock Market: Here's Why - Yahoo Finance
How did Grifols SA ADR (GRFS) fare last session? - US Post News
Ratios Revealed: Decoding Grifols SA ADR (GRFS)’s Financial Health - The Dwinnex
Grifols SA ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Are Investors Inclined To Sell Their Bath & Body Works Inc (NYSE: BBWI) Holdings? - Stocks Register
Does Uranium Royalty Corp (NASDAQ: UROY) Still Need To Convince Analysts? - Stocks Register
Finanzdaten der Grifols Sa Adr-Aktie (GRFS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):